A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06943521. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam
Study identification
- NCT ID
- NCT06943521
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Enrollment
- 27 participants
Conditions and interventions
Conditions
- Biliary Tract Cancer
- Breast Cancer
- Cervical Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Neuroendocrine Carcinoma (NEC)
- Neuroendocrine Tumor (NET)
- Non-small Cell Lung Cancer (NSCLC)
- Nuclear Protein in Testis (NUT) Carcinoma
- Ovarian Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Prostate Cancer
- Soft Tissue Sarcoma
- Urothelial Carcinoma
Interventions
- MT-4561 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 17, 2025
- Primary completion
- Jul 31, 2028
- Completion
- Jul 31, 2028
- Last update posted
- Dec 10, 2025
2025 – 2028
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90033 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06943521, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06943521 live on ClinicalTrials.gov.